✦ LIBER ✦

9164 An indirect comparison of the efficacy of bevacizumab plus cisplatin and gemcitabine (BCG) or bevacizumab plus carboplatin and paclitaxel (BCP) versus pemetrexed plus cisplatin (PC) and cetuximab plus vinorelbine and cisplatin (CVC) in patients (pts) with advanced or recurrent non-small cell cancer (NSCLC)

✍ Scribed by Walzer, S.; de Castro Carpeno, J.; Vergnenegre, A.V.; Chouaid, C.; Heigener, D.F.H.; Bischoff, H.G.; Nicolson, M.C.; Aultman, R.; Siebert, U.

Book ID: 122956592
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 48 KB
Volume: 7
Category: Article
ISSN: 1359-6349
DOI: 10.1016/S1359-6349(09)71877-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN14 AN INDIRECT COMPARISON OF THE EFFI

PCN14 AN INDIRECT COMPARISON OF THE EFFICACY OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) OR BEVACIZUMAB PLUS CARBOPLATIN AND PACLITAXEL (BCP) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)

✍ S Walzer; J de Castro Carpeño; A Vergnenegre; C Chouaid; D Heigener; HG Bischoff 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

PCN41 COST-SAVINGS ASSOCIATED WITH BEVAC

PCN41 COST-SAVINGS ASSOCIATED WITH BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) COMPARED WITH CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY

✍ D Heigener; HG Bischoff; C Wiesner; R Aultman 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

PCN89 A COST EFFECTIVENESS ANALYSIS DEMO

PCN89 A COST EFFECTIVENESS ANALYSIS DEMONSTRATES THE BENEFITS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN SPAIN

✍ J de Castro Carpeño; A Castro Gómez; S Walzer 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB

PCN80 THE BENEFITS OF BEVACIZUMAB PLUS C

PCN80 THE BENEFITS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN SWEDEN: RESULTS FROM A COST-EFFECTIVENESS ANALYSIS

✍ MJ Nuijten; C Holmberg; S Walzer 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB

PCN87 A COST-EFFECTIVENESS ANALYSIS OF B

PCN87 A COST-EFFECTIVENESS ANALYSIS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) COMPARED WITH PEMETREXED PLUS CISPLATIN (PC) FOR THE TREATMENT OF ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY

✍ HG Bischoff; D Heigener; C Wiesner; S Walzer 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

PCN29 THE COST SAVINGS ASSOCIATED WITH B

PCN29 THE COST SAVINGS ASSOCIATED WITH BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BEVACIZUMAB-BASED THERAPY) TREATMENT COMPARED WITH CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CETUXIMAB-BASED THERAPY) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL CANCER (NSCLC) ACROSS FOUR EUROPEAN COUNTRIES

✍ M Nuijten; C Chouaid; A Vergnenegre 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB